Are Third Parties Pharmaceutical Companies’ Achilles’ Heel?
For pharmaceutical and life science firms there has been nothing like the past 18 months. Faced with a 100-year pandemic that demanded unprecedented speeds in research and development while working under conditions that were unusual to say the least, these companies have had to collaborate with each other and with third parties as never before. […]
Proposed U.S. Interagency Guidance on Third-Party Relationships: Leveling the Playing Field for Third-Party Risk Management Requirements
On July 13, 2021, the Federal Reserve Board (FRB), the Office of the Comptroller of the Currency (OCC) and the Federal Deposit Insurance Corporation (FDIC) released a joint request for comment to their Proposed Interagency Guidance on Third-Party Relationships: Risk Management. The agencies have issued this proposed guidance in response to industry feedback requesting alignment […]
Effective Third-Party Risk Management During COVID-19 and Beyond
Organizations that rely on third parties to perform key services or deliver critical goods have had those relationships tested in 2020 as the COVID-19 pandemic caused critical vendors to become temporarily unavailable, change how they provide services, or forced them to go out of business altogether. Exports from China and other countries have been heavily […]
